The relationship between inflammation markers, positron emission tomography/ /computed tomography parameters and disease prognosis in advanced non-small-cell lung cancer patients

被引:0
|
作者
Pirincci, Esra [1 ]
Oruc, Zeynep [2 ]
Ebinc, Senar [3 ,6 ]
Guzel, Yunus [4 ]
Komek, Halil [4 ]
Kucukoner, Mehmet [5 ]
Urakci, Zuhat [2 ]
Kaplan, Muhammet Ali [2 ]
Tasdemir, Bekir [5 ]
Isikdogan, Abdurrahman
机构
[1] Dicle Univ, Fac Med, Dept Hematol, Diyarbakir, Turkiye
[2] Dicle Univ, Fac Med, Dept Med Oncol, Diyarbakir, Turkiye
[3] Gazi Yasargil Training & Res Hosp, Dept Med Oncol, Diyarbakir, Turkiye
[4] Gazi Yasargil Training & Res Hosp, Dept Nucl Med, Diyarbakir, Turkiye
[5] Dicle Univ, Fac Med, Dept Nucl Med, Diyarbakir, Turkiye
[6] Gazi Yasargil Training & Res Hosp, Dept Med Oncol, Billst Sur, TR-21280 Diyarbakir, Turkiye
来源
ONCOLOGY IN CLINICAL PRACTICE | 2024年 / 20卷 / 04期
关键词
inflammation; non-small-cell lung cancer; PET/CT; LYMPHOCYTE RATIO; NEUTROPHIL; MUTATIONS; SURVIVAL; OUTCOMES; PET/CT;
D O I
10.5603/ocp.97451
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction. Inflammation is known to be related to the development, spread, prognosis, and treatment response in cancer patients. Our study aimed to evaluate the correlation between inflammation indices and positron emission tomography-computed tomography (PET/CT) parameters and investigate their relationship with progression-free survival (PFS) and overall survival (OS) in patients diagnosed with stage-IV non -small cell lung cancer (NSCLC). Material and methods. Demographic, clinicopathological, laboratory, and PET/CT data of 179 patients diagnosed with stage-IV NSCLC who presented to the Oncology Department of Dicle University, Faculty of Medicine between 2010-2020 were retrieved from patient files and the hospital database system. Results. The median age at diagnosis was 64 (27-87) years. All patients included in the study had NSCLC: 72.6% had adenocarcinoma, 21.2% had squamous cell carcinoma, and 6.1% had other histological types. Of the 78 patients who were subjected to molecular analysis, 26 (33.3%) were EGFR-mutation positive. During the 10-month median follow-up, median first -line PFS was 6 months (95% CI 5.00-6.99), and median OS was 10 months (95% CI 7.8-12.1). The multivariate analysis performed for first -line PFS determined hemoglobin (HR = 1.01; 95% CI 1.003-1.02; p = 0.005) and PET total lesion glycolysis (TLG) (HR = 1.002; 95% CI 1.001-1.003; p = 0.003) values as independent prognostic factors. The multivariate analysis for OS determined positive EGFR mutation status (HR = 0.385; 95% CI 0.213-0.696; p = 0,014) and performance status (HR = 1.88; 95% CI 1.092-3.238; p = 0,008) as independent prognostic factors. Conclusions. Our study determined the hemoglobin level and PET TLG from PET/CT parameters to be independent prognostic factors for PFS, and performance status and EGFR mutation positivity to be independent prognostic factors for OS.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography
    Lardinois, D
    Weder, W
    Hany, TF
    Kamel, EM
    Korom, S
    Seifert, B
    von Schulthess, GK
    Steinert, HC
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (25): : 2500 - 2507
  • [2] Positron Emission Tomography/Computed Tomography Thoracic Nodal Staging of Non-Small-Cell Lung Cancer
    Cheung, W. S. K.
    HONG KONG JOURNAL OF RADIOLOGY, 2023, 26 (01): : 4 - 5
  • [3] The Role Of Positron Emission Tomography - Computed Tomography (PET/CT) In The Prognosis Of Patients With Non Small Cell Lung Cancer (NSCLC)
    Tesfaye, A.
    Mozayen, M.
    Sarangi, M.
    Nagpal, S.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S295 - S295
  • [4] Application of novel quantitative techniques for fluorodeoxyglucose positron emission tomography/computed tomography in patients with non-small-cell lung cancer
    Wang, Duo
    Koh, Eng-Siew
    Descallar, Joseph
    Pramana, Ariyanto
    Vinod, Shalini K.
    Shon, Ivan Ho
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 (04) : 349 - 358
  • [5] The association of metabolic positron emission tomography/computed tomography parameters with survival in small cell lung cancer
    Turk, Merve Ayik
    Komurcuoglu, Berna
    Aguloglu, Nursin
    Ciftci, Tugce Doksoz
    Fidan, Mucahit
    Colak, Sinan
    Batum, Ozgur
    ANNALS OF SAUDI MEDICINE, 2025, 45 (01) : 25 - 32
  • [6] Mediastinal lymph node staging of non-small-cell lung cancer: A prospective comparison of computed tomography and positron emission tomography
    Scott, WJ
    Gobar, LS
    Terry, JD
    Dewan, NA
    Sunderland, JJ
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1996, 111 (03): : 642 - 648
  • [7] Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer - A meta-analysis
    Gould, MK
    Kuschner, WG
    Rydzak, CE
    Maclean, CC
    Demas, AN
    Shigemitsu, H
    Chan, JK
    Owens, DK
    ANNALS OF INTERNAL MEDICINE, 2003, 139 (11) : 879 - 892
  • [8] Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non-small-cell lung cancer patients
    Wu, Yihua
    Li, Peiwei
    Zhang, Honghe
    Shi, Yu
    Wu, Han
    Zhang, Jinjie
    Qian, Yufeng
    Li, Chao
    Yang, Jun
    INTERNATIONAL JOURNAL OF CANCER, 2013, 132 (02) : E37 - E47
  • [9] Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography
    Bille, Andrea
    Pelosi, Ettore
    Skanjeti, Andrea
    Arena, Vincenzo
    Errico, Luca
    Borasio, Piero
    Mancini, Maurizio
    Ardissone, Francesco
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2009, 36 (03) : 440 - 445
  • [10] 18F-fluorodeoxyglucose positron emission tomography/computed tomography for predicting prognosis of small cell lung cancer patients
    Chen, X.
    Shen, L.
    Hong, Y.
    INTERNATIONAL JOURNAL OF RADIATION RESEARCH, 2023, 21 (02): : 211 - 215